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Th  e session on undue and disproportionate inﬂ  uences 
included three presentations that considered areas of 
profound importance for investigators involved with 
breast cancer research. Th  e ﬁ   rst two presentations 
focused on areas that substantially impact the inter  pre-
tation of scientiﬁ  c research, peer review and the topic of 
statistical signiﬁ  cance. Clearly, both these topics have an 
importance that extends beyond breast cancer to all 
research. Th  e third presentation considered whether 
randomized adjuvant therapy trials in early breast cancer 
were necessary for drug development, which is a topic of 
increasing importance given the increasing number of 
potentially valuable drugs that are in development and 
the corresponding increase in restrictions and limitations 
on funding available for the conduct of clinical research.
Peer review is considered the essential process by 
which judgments can be made regarding the quality of a 
manuscript, a grant proposal or other scholarly work. 
Despite acknowledgement of peer review as the corner-
stone for making these judgments, there is widespread 
appreciation of the shortcomings and deﬁ  ciencies of this 
process. Using his vast background as editor of a major 
journal, Doctor Richard Smith [1] provided his views on 
classical peer review. He deﬁ   ned peer review and 
addressed its problems before asking whether it could be 
done better and has undue inﬂ  uence. In doing so, insights 
into the process of manuscript review that might be 
considered provocative and controversial were put 
forward. Th   us, in deﬁ   ning peer review, Dr Smith 
indicated that there was no operational deﬁ  nition but 
that it was ‘something to do with a third party reviewing 
manuscripts and grant proposals before a ﬁ  nal decision is 
made’ Th   ere are as many peer review systems as there are 
journals and grant giving bodies. Convention has it that 
peer review serves to select the best studies, improve 
what is published and detect errors and fraud. However, 
Th  e Cochrane Collaboration [2,3] suggests that ‘At 
present, little empirical evidence is available to support 
the use of editorial peer review as a mechanism to ensure 
quality of biomedical research’ and ‘Th  ere is little 
empirical evidence on the eﬀ  ects of grant giving peer 
review. No studies assessing the impact of peer review on 
the quality of funded research are presently available.’ Dr 
Smith also indicated that the peer review process was 
frequently slow, expensive, time consuming and based on 
chance. It often failed to detect errors, can be biased and 
abused, and has a disproportionate inﬂ  uence on what is 
published and funded. Because of these characteristics, 
peer review is often a ﬂ  awed process that subtracts rather 
than adds value. Dr Smith advocated scrapping pre-
publication review and instead concentrating on real 
post-publication peer review (that will happen anyway). 
Th   e question of conducting open versus anonymous peer 
review was worthy of vigorous debate.
Professor Judith Bliss, Director of the Institute of 
Cancer Research Clinical Trials and Statistics Unit, 
provided a thoughtful and enlightening review of P-
values in the context of clinical research, a subject at the 
center of interpretation of such trials. She asked that 
investigators should be able to distinguish between 
probability of observing a diﬀ  erence as large as that seen 
when there is no diﬀ  erence between treatments group 
(correct statistical application of P-values) and proba-
bility that there is no diﬀ   erence between treatment 
groups given the data observed (popular misconception 
of P-values). Th   e origin for choosing ‘P < 0.05’ as a stan-
dard was traced back to Fisher in 1925 [4], although he 
was himself prepared to be ﬂ   exible when attributing 
signiﬁ  cance and fortitude with regard to actual P-values. 
Researchers were urged to interpret P-values in the 
context of the observations used to derive them and 
thereby not fall into the trap of allowing P-values to 
impair understanding of research results [5]. Speciﬁ  c 
examples were considered of ‘signiﬁ   cant but not 
substantial’ and vice versa. Professor Bliss also addressed 
the important issue of ‘clinical signiﬁ  cance’ in the setting 
of ‘statistical signiﬁ  cance’ and provided valuable insights 
into statistical considerations that are important to the 
clinician who must make judgments regarding ﬁ  ndings 
reported in the literature. © 2010 BioMed Central Ltd
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© 2010 BioMed Central LtdProfessor Joseph Ragaz [6], from the University of 
British Columbia School of Population and Public Health, 
addressed a major problem in the development of new 
therapeutic agents for breast cancer: the inordinately 
long time that is required to go from phase I trials to 
adjuvant trials and ultimately to accepted guidelines. He 
makes a compelling case for focusing on new approaches 
to expediting the drug development process on the basis 
of breast cancer recurrences, and deaths, that could be 
prevented by such an acceleration. His suggestions on 
how to approach this acceleration provide the basis for a 
lively discussion and debate on this important issue.
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